Back to search
FDAFDA · Food and drugs·Recall number D-1103-2023

Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactured for Baxter Healthcare Corporation, Deerfield, IL 60015, NDC 10019-079-01.

Published August 30, 2023 · Recall initiated: August 14, 2023

Summary

FDA records drug Class III recall D-1103-2023, published August 30, 2023 and initiated August 14, 2023. Recalling firm: Baxter Healthcare Corporation; Status: Completed; Reported quantity: 13,502 vials; Lot: Lots: 3A004A, 3A004B, Exp 12/31/2024; 3B005A, Exp 1/31/2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Missing Label; customer complaint received that labels were partially or completely peeled off injection vial.

What to do

Voluntary: Firm initiated · Letter

Get an email if BENDAMUSTINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BENDAMUSTINE HYDROCHLORIDE
Manufacturer
Baxter Healthcare Corporation
Distributor
Nationwide in the U.S.A.
Lot
Lots: 3A004A, 3A004B, Exp 12/31/2024; 3B005A, Exp 1/31/2025
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactured for Baxter Healthcare Corporation, Deerfield, IL 60015, NDC 10019-079-01. recalled?

Yes. FDA published recall D-1103-2023 on August 30, 2023. Reported hazard: Labeling: Missing Label; customer complaint received that labels were partially or completely peeled off injection vial.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BENDAMUSTINE HYDROCHLORIDE.